501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone: (604)
551-7831
Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix Achieves
New Benchmark for FAIMS Marijuana Breathalyzer
Technology
Cannabix is
developing Marijuana Breathalyzer devices to give law enforcement
and employers a tool to enhance public safety
Vancouver, British Columbia --
October 18, 2021 -- InvestorsHub NewsWire -- Cannabix Technologies
Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix") developer of
marijuana breathalyzer devices for law enforcement and the
workplace reports that engineers have made major advancements on
its high-field asymmetric waveform ion mobility spectrometry
("FAIMS") breathalyzer for analyte sensitivity and
portability.
In recent live breath testing of
marijuana smokers, the Cannabix FAIMS bench device has demonstrated
the sensitivity, resolution and discrete responses needed to
isolate ?9-tetrahydrocannabinol ("THC") - the psychoactive
component of marijuana that causes impairment as well as other key
marijuana metabolites (such as 11-hydroxy THC) and other
cannabinoids from the thousands of other compounds present in
breath.
This kind of
selectivity is significant because it provides far more
pharmacokinetic information than detection of THC alone, and can
allow for greater discernment of a subject's recency of cannabis
use.
This has been achieved
with a testing set up requiring only a few breaths which is
collected and analyzed on-site within seconds, without any sample
preparation needed. Development of the Cannabix FAIMS drug screen
device is aimed primarily for the law enforcement
market.
Furthermore, over recent months
engineers have focussed on systematically reducing the size of the
FAIMS electronics and components, and developing a fully battery
powered system, further paving the way for a portable device.
Engineers are building a novel system that meets the power and heat
dissipation requirements in the field for a complex high voltage
square wave generator. Critical achievements in relation to power
supply, air flow, cooling, electronics and detector module are well
underway and showing promising early results.
Cannabix is using its FAIMS
technology to detect ?9-tetrahydrocannabinol
("THC"),
a non-volatile compound, in breath. Breath testing for THC would
allow law enforcement to identify recent marijuana use that better
aligns with impairment. The Cannabix device has been designed and
built in a series of modules that together allow for sample intake,
ionization, filtering and detection - all done under atmospheric
pressure. In particular, the device uses ion mobility filtering
techniques (related to mass spectrometry - the gold standard
analytical technique for molecular detection). In addition, the
device has the ability to couple directly to a mass spectrometer in
order for chemical species validation.
About Cannabix Technologies
Inc.
Cannabix Technologies Inc. is a
developer of marijuana breathalyzer technologies for law
enforcement and the workplace. Cannabix is working to develop
drug-screening devices that will detect THC - the psychoactive
component of marijuana that causes impairment using breath samples.
Breath testing for THC would allow employers and law enforcement
to identify recent marijuana use that
better aligns with impairment. Cannabix devices are in the advanced
prototype and pre-clinical testing stage.
We seek Safe
Harbor.
On behalf of the
Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies
Inc.
For further information, contact
the Company at
info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that its development of marijuana
breathalyzer technology will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. There is no
assurance that existing "patent pending" technologies licensed by
the Company will receive patent status by regulatory
authorities.
The Company is not
currently selling commercial breathalyzers. Actual results and
future events could differ materially from those anticipated in
such information. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend to update these forward-looking
statements.